COVID19: Edited by Zhiwei Chen and Linqui ZhangTreatment of coronavirus disease 2019Hung, Ivan F.N.Author Information Infectious Disease Division, Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong SAR, China Correspondence to Ivan F.N. Hung, MD, Infectious Disease Division, Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong SAR, China. E-mail: firstname.lastname@example.org Current Opinion in HIV and AIDS: November 2020 - Volume 15 - Issue 6 - p 336-340 doi: 10.1097/COH.0000000000000652 Buy Metrics Abstract Purpose of review Coronavirus disease 2019 (COVID-19) is a highly contagious and potentially lethal pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). No specific antiviral treatment is currently available. The purpose of this review is to highlight the main repurposed drug treatments with in-vitro or in-vivo efficacy against the SARS-CoV-2. Recent findings Recent clinical trials suggested remdesivir, IFN-β-1b and favipiravir have potential clinical and/or virological benefits on patients with COVID-19. Short course of stress dose of corticosteroids might be used as adjunctive treatment to patients who are late presenters with cytokine storm. Convalescent plasma from recovered COVID-19 patients with high neutralizing antibody might also be beneficial in the treatment of severe disease. Summary Early effective antiviral therapy in COVID-19 patients will suppress the SARS-CoV-2 viral load. Adjunctive therapy with corticosteroid and convalescent plasma might further ameliorate the cytokine response. Further randomized clinical trials of combination therapy are needed. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.